共 50 条
- [41] Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept [J]. LIFE-BASEL, 2024, 14 (04):
- [42] Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration [J]. CLINICAL OPHTHALMOLOGY, 2023, 17 : 657 - 665
- [44] Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration [J]. LIFE-BASEL, 2023, 13 (02):
- [47] RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Systematic Review of Real-World Evidence [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2023, 43 (07): : 1051 - 1063